US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ARS PHARMACEUTICALS INC

9.14

-0.0700-0.76%

Post-market: 9.140.00000.00%16:04 EST

Volume:677.34K

Turnover:6.20M

Market Cap:903.48M

PE:-11.21

High:9.33

Open:9.18

Low:9.04

Close:9.21

52wk High:18.90

52wk Low:6.66

Shares:98.85M

Float Shares:55.27M

Volume Ratio:0.90

T/O Rate:1.23%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.8154

EPS(LYR):0.0800

ROE:-45.92%

ROA:-19.22%

PB:6.12

PE(LYR):114.25

Loading ...

Overview Company News Filings

ARS Pharmaceuticals Q3 EPS $(0.52) Misses $(0.47) Estimate, Sales $32.501M Beat $28.743M Estimate

ARS Pharmaceuticals Q3 Net Income USD -51.151 Million

THOMSON REUTERS

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for Neffy® (Epinephrine Nasal Spray)

THOMSON REUTERS

Press Release: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy(R) (epinephrine nasal spray)

ARS Pharma Launches GET Neffy® on US for Patients With Severe Allergic Reactions to Improve Access to Neffy (Epinephrine Nasal Spray)

THOMSON REUTERS

ARS Pharmaceuticals resumed with a Buy at Roth Capital

ARS Pharmaceuticals Inc. to Release Third Quarter 2025 Financial Results

ARS Pharmaceuticals Reports Real-World Success of Intranasal Epinephrine neffy in Treating Anaphylaxis

ARS Pharmaceuticals Says European Patent Office Upholds Nasal Spray Epinephrine Patent

MT Newswires Live

European Patent Office Upholds ARS Patent for Nasal Spray to Treat Allergic Reaction

BRIEF-ARS Pharmaceuticals Receives Favorable Decision From European Patent Office On Patent Related To Neffy® (Epinephrine Nasal Spray)

ARS Pharmaceuticals : Global Intellectual Property Portfolio Related to Neffy Provides Coverage Until at Least 2039

THOMSON REUTERS

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility from RA Capital and OMERS Life Sciences to Accelerate neffy® Commercialization

ARS Pharmaceuticals Secures up to $250 Million Loan Facility With Ra Capital Management and Omers Life Sciences to Accelerate U.S. Commercialization of Neffy®

THOMSON REUTERS

ARS Pharmaceuticals Inc - ARS Pharma Borrows Initial $100 Mln to Accelerate Neffy Growth

THOMSON REUTERS

Sector Update: Health Care Stocks Mixed Friday Afternoon

MT Newswires Live

Sector Update: Health Care Stocks Rise Pre-Bell Friday

MT Newswires Live

ARS Pharmaceuticals Says Japan Regulator Approves Neffy Nasal Spray

MT Newswires Live

ARS Pharmaceuticals Inc - Neffy Expected to Be Available in Japan in Q4 2025

THOMSON REUTERS

Neffy® (Epinephrine Nasal Spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (Anaphylaxis)

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SPRY/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SPRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":9.14,"timestamp":1771966800000,"preClose":9.21,"halted":0,"volume":677338,"hourTrading":{"tag":"盘后","latestPrice":9.14,"preClose":9.14,"latestTime":"16:04 EST","volume":15920,"amount":145508.80000000002,"timestamp":1771967064621,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.007600434310532061,"floatShares":55270496,"shares":98848611,"eps":-0.81541,"marketStatus":"Post-Mkt","change":-0.07,"latestTime":"02-24 16:08:05 EST","open":9.18,"high":9.33,"low":9.04,"amount":6199992.563,"amplitude":0.031488,"askPrice":9.5,"askSize":125,"bidPrice":8.75,"bidSize":125,"shortable":3,"etf":0,"ttmEps":-0.81541,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771981200000},"marketStatusCode":4,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":9.21,"preHourTrading":{"tag":"盘前","latestPrice":9.25,"preClose":9.21,"latestTime":"09:03 EST","volume":864,"amount":8005.318560000001,"timestamp":1771941816473,"change":0.04,"changeRate":0.004343,"amplitude":0.010858},"postHourTrading":{"tag":"盘后","latestPrice":9.14,"preClose":9.14,"latestTime":"16:04 EST","volume":15920,"amount":145508.80000000002,"timestamp":1771967064621,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.902256,"impliedVol":1.1492,"impliedVolPercentile":0.8207},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","floatShares":55270496,"roa":"-19.22%","roe":"-45.92%","lyrEps":0.079999,"volumeRatio":0.902256,"shares":98848611,"dividePrice":0,"high":9.33,"amplitude":0.031488,"preClose":9.21,"low":9.04,"week52Low":6.66,"pbRate":"6.12","psRate":"6.33","week52High":18.9,"institutionHeld":0,"latestPrice":9.14,"eps":-0.81541,"divideRate":0,"volume":677338,"delay":0,"ttmEps":-0.81541,"open":9.18,"prevYearClose":11.65,"prevWeekClose":9,"prevMonthClose":9.99,"prevQuarterClose":11.65,"fiveDayClose":9.38,"twentyDayClose":10.48,"sixtyDayClose":9.28,"earningDate":1772985600000,"earningTime":"盘前"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPRY\",params:#limit:5,,,undefined,":[{"date":"2026-03-09","symbol":"SPRY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":-0.42,"defaultRemindTime":1773043200000,"name":null,"time":"Pre-Market","dateTimestamp":1773028800000,"actualEps":null},{"market":"US","date":"2025-11-10","symbol":"SPRY","fiscalQuarterEnding":"2025/09","expectedEps":-0.45,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.52},{"market":"US","date":"2025-08-13","symbol":"SPRY","fiscalQuarterEnding":"2025/06","expectedEps":-0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-0.46},{"market":"US","date":"2025-05-14","symbol":"SPRY","fiscalQuarterEnding":"2025/03","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"pre","actualEps":-0.35},{"market":"US","date":"2025-03-20","symbol":"SPRY","fiscalQuarterEnding":"2024/12","expectedEps":-0.04,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"pre","actualEps":0.52}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPRY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":6,"updateTime":1762491600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SPRY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SPRY","date":"2026-02-23","current":-11.196821,"percent":0.825316,"low":-115.157754,"twenty":-29.837472,"median":-17.926513,"eighty":-12.05734,"high":184.020638,"avg":-16.950915,"sd":47.61546,"marketCap":889637499},"quantilePoints":[{"date":"2022-11-11","current":-28.534516,"twenty":-28.349227,"median":-28.071294,"eighty":-27.904534,"marketCap":577624216},{"date":"2022-11-18","current":-27.515427,"twenty":-28.349227,"median":-28.00181,"eighty":-27.867476,"marketCap":556994780},{"date":"2022-11-25","current":-28.627161,"twenty":-29.164499,"median":-28.302905,"eighty":-27.978649,"marketCap":579499619},{"date":"2022-12-02","current":-32.332942,"twenty":-29.813011,"median":-28.534516,"eighty":-27.978649,"marketCap":654515751},{"date":"2022-12-09","current":-33.352032,"twenty":-32.629404,"median":-28.951417,"eighty":-27.987913,"marketCap":675145188},{"date":"2022-12-16","current":-37.428392,"twenty":-33.870842,"median":-29.970507,"eighty":-28.034236,"marketCap":757662933},{"date":"2022-12-23","current":-37.428392,"twenty":-36.761351,"median":-31.221208,"eighty":-28.136145,"marketCap":757662933},{"date":"2022-12-30","current":-39.512894,"twenty":-37.428392,"median":-32.842487,"eighty":-28.39555,"marketCap":799859507},{"date":"2023-01-06","current":-33.490999,"twenty":-37.558094,"median":-33.236227,"eighty":-28.506723,"marketCap":677958292},{"date":"2023-01-13","current":-34.510089,"twenty":-37.428392,"median":-33.352032,"eighty":-28.608632,"marketCap":698587729},{"date":"2023-01-20","current":-24.704541,"twenty":-37.261632,"median":-32.981454,"eighty":-28.089644,"marketCap":627322403},{"date":"2023-01-27","current":-23.338221,"twenty":-36.955904,"median":-32.518231,"eighty":-27.978649,"marketCap":592627442},{"date":"2023-02-03","current":-26.292426,"twenty":-36.631648,"median":-30.109473,"eighty":-26.233342,"marketCap":667643574},{"date":"2023-02-10","current":-28.323442,"twenty":-36.44636,"median":-29.576768,"eighty":-26.233342,"marketCap":719217165},{"date":"2023-02-17","current":-31.868488,"twenty":-36.103575,"median":-29.970507,"eighty":-27.026227,"marketCap":809236523},{"date":"2023-02-24","current":-30.539096,"twenty":-35.51065,"median":-30.109473,"eighty":-27.543213,"marketCap":775479264},{"date":"2023-03-03","current":-33.641011,"twenty":-34.760229,"median":-30.612951,"eighty":-27.668279,"marketCap":854246203},{"date":"2023-03-10","current":-29.025066,"twenty":-34.306271,"median":-30.649879,"eighty":-27.867476,"marketCap":737033496},{"date":"2023-03-17","current":-31.056082,"twenty":-33.963486,"median":-30.631415,"eighty":-27.978649,"marketCap":788607087},{"date":"2023-03-24","current":-20.659679,"twenty":-33.801144,"median":-30.612951,"eighty":-27.867476,"marketCap":716518982},{"date":"2023-03-31","current":-17.719962,"twenty":-33.618064,"median":-30.576023,"eighty":-26.2038,"marketCap":614563712},{"date":"2023-04-06","current":-15.732931,"twenty":-33.565575,"median":-30.176574,"eighty":-25.70897,"marketCap":545649501},{"date":"2023-04-14","current":-16.631178,"twenty":-33.492841,"median":-29.970507,"eighty":-24.113699,"marketCap":576802501},{"date":"2023-04-21","current":-17.973502,"twenty":-33.463206,"median":-29.344076,"eighty":-23.419462,"marketCap":623356984},{"date":"2023-04-28","current":-17.210989,"twenty":-33.352032,"median":-29.090384,"eighty":-19.070054,"marketCap":596911536},{"date":"2023-05-05","current":-16.693286,"twenty":-33.350744,"median":-28.918758,"eighty":-18.073817,"marketCap":578956528},{"date":"2023-05-12","current":-12.329028,"twenty":-33.323434,"median":-28.627161,"eighty":-17.841072,"marketCap":427595344},{"date":"2023-05-19","current":-17.294264,"twenty":-33.212652,"median":-28.359496,"eighty":-17.789501,"marketCap":733155735},{"date":"2023-05-26","current":-17.057707,"twenty":-33.123305,"median":-28.101877,"eighty":-17.789501,"marketCap":723127390},{"date":"2023-06-02","current":-15.358643,"twenty":-33.120421,"median":-28.024971,"eighty":-17.719962,"marketCap":651098973},{"date":"2023-06-09","current":-15.179795,"twenty":-32.981454,"median":-27.978649,"eighty":-17.665522,"marketCap":643517035},{"date":"2023-06-16","current":-13.525443,"twenty":-32.939388,"median":-27.584891,"eighty":-17.230009,"marketCap":573384103},{"date":"2023-06-23","current":-14.352619,"twenty":-32.898926,"median":-26.292426,"eighty":-16.984823,"marketCap":608450569},{"date":"2023-06-30","current":-14.777385,"twenty":-32.852687,"median":-26.033933,"eighty":-16.443167,"marketCap":626457673},{"date":"2023-07-07","current":-14.374975,"twenty":-32.778571,"median":-25.664657,"eighty":-16.200645,"marketCap":609398311},{"date":"2023-07-14","current":-15.381,"twenty":-32.650157,"median":-24.815323,"eighty":-15.896248,"marketCap":652046716},{"date":"2023-07-20","current":-16.342312,"twenty":-32.522678,"median":-23.947525,"eighty":-15.738555,"marketCap":692799635},{"date":"2023-07-28","current":-14.889165,"twenty":-32.268091,"median":-23.449004,"eighty":-15.666005,"marketCap":631196385},{"date":"2023-08-04","current":-15.649273,"twenty":-31.980646,"median":-22.434463,"eighty":-15.664922,"marketCap":663419624},{"date":"2023-08-11","current":-12.27233,"twenty":-31.772476,"median":-20.321699,"eighty":-15.577733,"marketCap":654642902},{"date":"2023-08-18","current":-12.05734,"twenty":-31.358888,"median":-18.902086,"eighty":-15.443597,"marketCap":643174706},{"date":"2023-08-25","current":-12.361909,"twenty":-31.218563,"median":-18.499284,"eighty":-15.287104,"marketCap":659421318},{"date":"2023-08-30","current":-12.70231,"twenty":-31.152094,"median":-18.359623,"eighty":-15.152968,"marketCap":677579296},{"date":"2023-09-08","current":-13.114373,"twenty":-31.100395,"median":-18.231502,"eighty":-15.005417,"marketCap":699560007},{"date":"2023-09-15","current":-13.04271,"twenty":-31.033926,"median":-18.031385,"eighty":-14.777385,"marketCap":695737274},{"date":"2023-09-20","current":-11.833393,"twenty":-31.022847,"median":-18.002563,"eighty":-14.750557,"marketCap":631228667},{"date":"2023-09-27","current":-6.718429,"twenty":-31.011769,"median":-17.988032,"eighty":-14.670075,"marketCap":358381151},{"date":"2023-10-05","current":-7.166324,"twenty":-30.867751,"median":-17.964938,"eighty":-14.419687,"marketCap":382273228},{"date":"2023-10-13","current":-6.718429,"twenty":-30.668342,"median":-17.875755,"eighty":-14.196126,"marketCap":358381151},{"date":"2023-10-20","current":-6.055544,"twenty":-30.649879,"median":-17.782874,"eighty":-14.047454,"marketCap":323020877},{"date":"2023-10-27","current":-6.306365,"twenty":-30.649879,"median":-17.728408,"eighty":-14.012806,"marketCap":336400440},{"date":"2023-11-03","current":-6.539271,"twenty":-30.635108,"median":-17.710569,"eighty":-13.713234,"marketCap":348824320},{"date":"2023-11-10","current":-5.319172,"twenty":-30.612951,"median":-17.665522,"eighty":-13.225451,"marketCap":327799293},{"date":"2023-11-17","current":-7.025405,"twenty":-30.612951,"median":-17.36121,"eighty":-12.859969,"marketCap":432947606},{"date":"2023-11-24","current":-7.41484,"twenty":-30.59818,"median":-17.220775,"eighty":-12.627063,"marketCap":456946919},{"date":"2023-12-01","current":-7.523882,"twenty":-30.480012,"median":-17.057707,"eighty":-12.494486,"marketCap":463666727},{"date":"2023-12-08","current":-8.1314,"twenty":-30.216835,"median":-16.553813,"eighty":-12.335604,"marketCap":501105655},{"date":"2023-12-15","current":-8.115823,"twenty":-30.090944,"median":-16.431736,"eighty":-12.243664,"marketCap":500145682},{"date":"2023-12-22","current":-7.944471,"twenty":-30.007565,"median":-16.309818,"eighty":-8.996418,"marketCap":489585985},{"date":"2023-12-29","current":-8.770073,"twenty":-29.979771,"median":-16.222884,"eighty":-8.287174,"marketCap":540464528},{"date":"2024-01-05","current":-8.785651,"twenty":-29.917293,"median":-16.174641,"eighty":-8.399331,"marketCap":541424501},{"date":"2024-01-12","current":-9.112776,"twenty":-29.704533,"median":-16.005127,"eighty":-8.58626,"marketCap":561583924},{"date":"2024-01-19","current":-9.471056,"twenty":-29.440705,"median":-15.977907,"eighty":-8.629876,"marketCap":583663292},{"date":"2024-01-26","current":-10.156461,"twenty":-29.180978,"median":-15.857321,"eighty":-8.707763,"marketCap":625902083},{"date":"2024-02-02","current":-9.969533,"twenty":-29.156298,"median":-15.732931,"eighty":-8.773189,"marketCap":614382412},{"date":"2024-02-09","current":-10.109729,"twenty":-29.07732,"median":-15.682807,"eighty":-8.798113,"marketCap":623022165},{"date":"2024-02-16","current":-11.309188,"twenty":-29.025066,"median":-15.649273,"eighty":-8.900923,"marketCap":696940049},{"date":"2024-02-23","current":-11.83882,"twenty":-29.025066,"median":-15.515136,"eighty":-9.112776,"marketCap":729579115},{"date":"2024-03-01","current":-13.038279,"twenty":-28.81245,"median":-15.453657,"eighty":-9.20624,"marketCap":803496999},{"date":"2024-03-08","current":-13.941768,"twenty":-28.8035,"median":-15.381,"eighty":-9.20624,"marketCap":859175405},{"date":"2024-03-15","current":-14.019655,"twenty":-28.627161,"median":-15.258041,"eighty":-9.237395,"marketCap":863975268},{"date":"2024-03-22","current":-15.975609,"twenty":-28.534516,"median":-15.179795,"eighty":-9.252972,"marketCap":868513986},{"date":"2024-03-28","current":-17.679674,"twenty":-28.423343,"median":-15.269219,"eighty":-9.315282,"marketCap":961155477},{"date":"2024-04-05","current":-16.916395,"twenty":-28.337864,"median":-15.369822,"eighty":-9.405631,"marketCap":919659809},{"date":"2024-04-12","current":-16.401625,"twenty":-28.264358,"median":-15.43689,"eighty":-9.46171,"marketCap":891674358},{"date":"2024-04-19","current":-14.981571,"twenty":-28.131419,"median":-15.49278,"eighty":-9.483518,"marketCap":814473115},{"date":"2024-04-26","current":-14.360297,"twenty":-28.077411,"median":-15.403356,"eighty":-9.636176,"marketCap":780697571},{"date":"2024-05-03","current":-16.860498,"twenty":-28.034236,"median":-15.420123,"eighty":-9.72341,"marketCap":916620967},{"date":"2024-05-10","current":-17.157732,"twenty":-27.987913,"median":-15.505955,"eighty":-9.779488,"marketCap":852670667},{"date":"2024-05-17","current":-17.742813,"twenty":-27.978649,"median":-15.537492,"eighty":-9.809086,"marketCap":881746829},{"date":"2024-05-24","current":-17.157885,"twenty":-27.978649,"median":-15.649273,"eighty":-9.876069,"marketCap":852678252},{"date":"2024-05-31","current":-17.313866,"twenty":-27.867476,"median":-15.716341,"eighty":-9.910338,"marketCap":860429873},{"date":"2024-06-07","current":-17.177383,"twenty":-27.668279,"median":-15.746992,"eighty":-9.932147,"marketCap":853647205},{"date":"2024-06-14","current":-16.884919,"twenty":-27.543213,"median":-15.872834,"eighty":-9.957071,"marketCap":839112916},{"date":"2024-06-21","current":-15.929536,"twenty":-27.026227,"median":-15.872834,"eighty":-9.981995,"marketCap":791634241},{"date":"2024-06-28","current":-16.592455,"twenty":-26.233342,"median":-15.857321,"eighty":-10.038073,"marketCap":824578628},{"date":"2024-07-05","current":-17.742813,"twenty":-26.122559,"median":-15.901185,"eighty":-10.097267,"marketCap":881746829},{"date":"2024-07-12","current":-22.129772,"twenty":-26.004391,"median":-15.977907,"eighty":-10.112844,"marketCap":1099761155},{"date":"2024-07-19","current":-20.550467,"twenty":-25.84191,"median":-16.008119,"eighty":-10.131537,"marketCap":1021275998},{"date":"2024-07-26","current":-21.408361,"twenty":-25.598187,"median":-16.06602,"eighty":-10.234348,"marketCap":1063909910},{"date":"2024-08-02","current":-19.302621,"twenty":-25.251068,"median":-16.155521,"eighty":-10.620668,"marketCap":959263034},{"date":"2024-08-09","current":-23.520911,"twenty":-24.881793,"median":-16.206368,"eighty":-10.941562,"marketCap":1054724705},{"date":"2024-08-16","current":-28.81744,"twenty":-25.84191,"median":-16.286222,"eighty":-11.035026,"marketCap":1292231647},{"date":"2024-08-23","current":-28.017556,"twenty":-27.270827,"median":-16.393243,"eighty":-11.081758,"marketCap":1256363252},{"date":"2024-08-30","current":-28.060793,"twenty":-27.941591,"median":-16.401625,"eighty":-11.197031,"marketCap":1258302084},{"date":"2024-09-06","current":-24.558599,"twenty":-27.79336,"median":-16.442915,"eighty":-11.309188,"marketCap":1101256678},{"date":"2024-09-13","current":-28.752585,"twenty":-27.79336,"median":-16.472628,"eighty":-11.620736,"marketCap":1289323399},{"date":"2024-09-20","current":-31.930502,"twenty":-27.995938,"median":-16.576918,"eighty":-11.620736,"marketCap":1431827564},{"date":"2024-09-27","current":-30.95767,"twenty":-28.060793,"median":-16.631178,"eighty":-11.714201,"marketCap":1388203840},{"date":"2024-10-04","current":-30.67663,"twenty":-28.212122,"median":-16.751589,"eighty":-11.833393,"marketCap":1375601431},{"date":"2024-10-11","current":-31.39004,"twenty":-28.39555,"median":-16.860498,"eighty":-11.83882,"marketCap":1407592162},{"date":"2024-10-18","current":-34.567957,"twenty":-28.752585,"median":-16.884919,"eighty":-11.967761,"marketCap":1550096327},{"date":"2024-10-25","current":-31.930502,"twenty":-28.968769,"median":-17.021402,"eighty":-12.05734,"marketCap":1431827564},{"date":"2024-11-01","current":-32.989808,"twenty":-29.172776,"median":-17.10772,"eighty":-12.236498,"marketCap":1479328953},{"date":"2024-11-08","current":-36.837898,"twenty":-29.53085,"median":-17.177383,"eighty":-12.27233,"marketCap":1651885017},{"date":"2024-11-15","current":-27.728261,"twenty":-29.574087,"median":-17.203935,"eighty":-12.290246,"marketCap":1361568504},{"date":"2024-11-22","current":-27.708469,"twenty":-29.53085,"median":-17.216378,"eighty":-12.329028,"marketCap":1360596650},{"date":"2024-11-29","current":-28.717849,"twenty":-29.510269,"median":-17.294264,"eighty":-12.329028,"marketCap":1410161242},{"date":"2024-12-06","current":-27.748052,"twenty":-29.318167,"median":-17.323614,"eighty":-12.355333,"marketCap":1362540359},{"date":"2024-12-13","current":-23.552198,"twenty":-29.200708,"median":-17.377363,"eighty":-12.390575,"marketCap":1156507152},{"date":"2024-12-20","current":-22.127191,"twenty":-29.174826,"median":-17.429503,"eighty":-12.426406,"marketCap":1086533610},{"date":"2024-12-27","current":-21.355313,"twenty":-29.123341,"median":-17.460097,"eighty":-12.465821,"marketCap":1048631275},{"date":"2025-01-03","current":-22.146983,"twenty":-29.064257,"median":-17.508842,"eighty":-12.501652,"marketCap":1087505465},{"date":"2025-01-10","current":-22.245942,"twenty":-29.025066,"median":-17.556082,"eighty":-12.530317,"marketCap":1092364739},{"date":"2025-01-17","current":-24.878247,"twenty":-29.013807,"median":-17.625827,"eighty":-12.566149,"marketCap":1221621420},{"date":"2025-01-24","current":-27.866803,"twenty":-28.968769,"median":-17.665522,"eighty":-12.594815,"marketCap":1368371488},{"date":"2025-01-31","current":-25.768876,"twenty":-28.968769,"median":-17.692748,"eighty":-12.61273,"marketCap":1265354884},{"date":"2025-02-07","current":-23.591782,"twenty":-28.81744,"median":-17.719962,"eighty":-12.684394,"marketCap":1158450862},{"date":"2025-02-14","current":-23.7897,"twenty":-28.81245,"median":-17.725862,"eighty":-12.70231,"marketCap":1168169409},{"date":"2025-02-21","current":-22.245942,"twenty":-28.80529,"median":-17.742813,"eighty":-12.730975,"marketCap":1092364739},{"date":"2025-02-28","current":-20.741768,"twenty":-28.766646,"median":-17.750677,"eighty":-12.878556,"marketCap":1018503778},{"date":"2025-03-07","current":-21.474063,"twenty":-28.753554,"median":-17.783612,"eighty":-12.988431,"marketCap":1054462403},{"date":"2025-03-14","current":-23.492823,"twenty":-28.724796,"median":-17.918291,"eighty":-13.032048,"marketCap":1153591588},{"date":"2025-03-21","current":151.633005,"twenty":-28.645299,"median":-17.929848,"eighty":-12.988431,"marketCap":1212760777},{"date":"2025-03-28","current":153.227851,"twenty":-28.604711,"median":-17.78435,"eighty":-12.670061,"marketCap":1225516351},{"date":"2025-04-04","current":157.030944,"twenty":-28.551598,"median":-17.756493,"eighty":-12.515985,"marketCap":1255933491},{"date":"2025-04-11","current":172.365997,"twenty":-28.537065,"median":-17.742813,"eighty":-12.355333,"marketCap":1378583246},{"date":"2025-04-17","current":182.548472,"twenty":-28.53527,"median":-17.728408,"eighty":-12.28308,"marketCap":1460022683},{"date":"2025-04-25","current":168.930945,"twenty":-28.478265,"median":-17.719962,"eighty":-11.916185,"marketCap":1351109701},{"date":"2025-05-02","current":177.55989,"twenty":-28.413636,"median":-17.701176,"eighty":-11.620736,"marketCap":1420124003},{"date":"2025-05-09","current":165.034919,"twenty":-28.363303,"median":-17.672598,"eighty":-11.047488,"marketCap":1319949281},{"date":"2025-05-16","current":-85.348526,"twenty":-28.478265,"median":-17.679674,"eighty":-10.985179,"marketCap":1335704429},{"date":"2025-05-23","current":-91.122103,"twenty":-28.610323,"median":-17.701176,"eighty":-11.047488,"marketCap":1426060905},{"date":"2025-05-30","current":-97.209461,"twenty":-28.755493,"median":-17.719962,"eighty":-11.103567,"marketCap":1521328059},{"date":"2025-06-06","current":-84.344425,"twenty":-28.908237,"median":-17.728408,"eighty":-11.22507,"marketCap":1319990259},{"date":"2025-06-13","current":-90.369027,"twenty":-29.139819,"median":-17.742813,"eighty":-11.433807,"marketCap":1414275278},{"date":"2025-06-20","current":-99.845224,"twenty":-29.414401,"median":-17.756493,"eighty":-11.620736,"marketCap":1562577755},{"date":"2025-06-27","current":-113.463334,"twenty":-29.625971,"median":-17.78435,"eighty":-11.639429,"marketCap":1775701182},{"date":"2025-07-03","current":-103.673356,"twenty":-29.970507,"median":-17.918291,"eighty":-11.714201,"marketCap":1622488027},{"date":"2025-07-11","current":-112.835772,"twenty":-30.109473,"median":-17.96922,"eighty":-11.833393,"marketCap":1765879826},{"date":"2025-07-18","current":-115.157754,"twenty":-30.373971,"median":-18.060207,"eighty":-11.83882,"marketCap":1802218844},{"date":"2025-07-25","current":-112.459234,"twenty":-30.612951,"median":-18.156476,"eighty":-11.967761,"marketCap":1759987013},{"date":"2025-08-01","current":-110.953084,"twenty":-30.649879,"median":-18.318793,"eighty":-12.05734,"marketCap":1736415758},{"date":"2025-08-08","current":-110.764815,"twenty":-30.849578,"median":-18.491503,"eighty":-12.236498,"marketCap":1733469351},{"date":"2025-08-15","current":-29.781475,"twenty":-31.056082,"median":-18.779127,"eighty":-12.27233,"marketCap":1430017096},{"date":"2025-09-05","current":-22.001657,"twenty":-31.011769,"median":-19.029654,"eighty":-12.286663,"marketCap":1056453542},{"date":"2025-09-12","current":-20.890254,"twenty":-30.966274,"median":-19.71207,"eighty":-12.321272,"marketCap":1003087320},{"date":"2025-09-19","current":-20.43746,"twenty":-30.871196,"median":-20.12152,"eighty":-12.329028,"marketCap":981345526},{"date":"2025-09-26","current":-19.63478,"twenty":-30.797693,"median":-20.134768,"eighty":-12.355333,"marketCap":942803254},{"date":"2025-10-03","current":-21.157814,"twenty":-30.698248,"median":-20.149319,"eighty":-12.390575,"marketCap":1015934744},{"date":"2025-10-10","current":-23.833413,"twenty":-30.67,"median":-20.178749,"eighty":-12.426406,"marketCap":1144408982},{"date":"2025-10-17","current":-20.807928,"twenty":-30.653572,"median":-20.2775,"eighty":-12.47657,"marketCap":999134267},{"date":"2025-10-24","current":-19.861177,"twenty":-30.649879,"median":-20.299599,"eighty":-12.515985,"marketCap":953674152},{"date":"2025-10-31","current":-17.74128,"twenty":-30.620337,"median":-20.187599,"eighty":-12.551817,"marketCap":851883024},{"date":"2025-11-07","current":-16.866565,"twenty":-30.612951,"median":-20.149319,"eighty":-12.587649,"marketCap":809881831},{"date":"2025-11-14","current":-10.386267,"twenty":-30.612951,"median":-20.12152,"eighty":-12.426406,"marketCap":831316818},{"date":"2025-11-21","current":-8.311484,"twenty":-30.553867,"median":-19.933213,"eighty":-12.321272,"marketCap":665251152},{"date":"2025-11-28","current":-11.781806,"twenty":-30.491905,"median":-19.75827,"eighty":-12.164835,"marketCap":943015748},{"date":"2025-12-05","current":-12.312852,"twenty":-30.408561,"median":-19.63478,"eighty":-11.836649,"marketCap":985520651},{"date":"2025-12-12","current":-13.856589,"twenty":-30.373971,"median":-19.314339,"eighty":-11.916185,"marketCap":1109081415},{"date":"2025-12-19","current":-12.127603,"twenty":-30.309116,"median":-19.029654,"eighty":-12.021508,"marketCap":970693360},{"date":"2025-12-26","current":-14.177687,"twenty":-30.256997,"median":-18.779127,"eighty":-12.085445,"marketCap":1134782054},{"date":"2026-01-02","current":-14.387635,"twenty":-30.230821,"median":-18.672648,"eighty":-12.149382,"marketCap":1151586318},{"date":"2026-01-09","current":-13.523142,"twenty":-30.165419,"median":-18.491503,"eighty":-12.241889,"marketCap":1082392290},{"date":"2026-01-16","current":-13.696041,"twenty":-30.101841,"median":-18.441052,"eighty":-12.263452,"marketCap":1096231095},{"date":"2026-01-23","current":-13.053846,"twenty":-30.071312,"median":-18.318793,"eighty":-12.263452,"marketCap":1044829818},{"date":"2026-01-30","current":-12.621599,"twenty":-30.016829,"median":-18.156476,"eighty":-12.27233,"marketCap":1010232804},{"date":"2026-02-06","current":-11.942355,"twenty":-30.006457,"median":-18.060207,"eighty":-12.27233,"marketCap":955866068},{"date":"2026-02-13","current":-10.880263,"twenty":-29.970507,"median":-17.96922,"eighty":-12.251102,"marketCap":870856262},{"date":"2026-02-20","current":-11.658307,"twenty":-29.864079,"median":-17.933958,"eighty":-12.08391,"marketCap":933130887},{"date":"2026-02-23","current":-11.114911,"twenty":-29.837472,"median":-17.926513,"eighty":-12.05734,"marketCap":889637499}],"updateTime":1771945250450},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPRY\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2582827210","title":"ARS Pharmaceuticals Q3 EPS $(0.52) Misses $(0.47) Estimate, Sales $32.501M Beat $28.743M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582827210","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582827210?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772450,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.47) by 10.17 percent. This is a 160 percent decrease over losses of $(0.20) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48746889/ars-pharmaceuticals-q3-eps-0-52-misses-0-47-estimate-sales-32-501m-beat-28-743m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2582449827","title":"ARS Pharmaceuticals Q3 Net Income USD -51.151 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582449827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582449827?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX59838A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2582827267","title":"ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights  for Neffy® (Epinephrine Nasal Spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582827267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582827267?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA6TWGML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2582827905","title":"Press Release: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy(R) (epinephrine nasal spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582827905","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582827905?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772400,"startTime":"0","endTime":"0","summary":"$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025. Continued U.S. product growth driven by direct-to-consumer  investments and real-world evidence, expected to accelerate with seamless prescribing experience. Strong balance sheet of $288.2 million cash, cash equivalents and short-term investments anticipated to fund operations through cash-flow break-even. \"We are executing our commercial strategy across multiple fronts, with each element reinforcing the others to drive momentum,\" said Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma. \"Our direct-to-consumer campaigns are generating measurable increases in patient awareness; real-world evidence data are further strengthening prescriber confidence in neffy's effectiveness; and we are implementing advertising programs such as a free virtual prescriber option and zero dollar co-pay to further reduce barriers for patients, so that when healthcare providers want their ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALK","SPRY","BK4500","R","BK4203","NHI","BK4232","BK4588","BK4225","EMA","HCP","BK4023","BK4022","BK4081","BK4585","BK4139","BK4008"],"gpt_icon":0},{"id":"2580373141","title":"ARS Pharma Launches GET Neffy® on US for Patients With Severe Allergic Reactions to Improve Access to Neffy (Epinephrine Nasal Spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580373141","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580373141?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:00","pubTimestamp":1762261210,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA3HTWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2580731792","title":"ARS Pharmaceuticals resumed with a Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2580731792","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580731792?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:55","pubTimestamp":1762260928,"startTime":"0","endTime":"0","summary":"Roth Capital analyst Kyle Bauser resumed coverage of ARS Pharmaceuticals (SPRY) with a Buy rating and $30 price target The firm is anticipating sig...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-resumed-with-a-buy-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-resumed-with-a-buy-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2580421351","title":"ARS Pharmaceuticals Inc. to Release Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2580421351","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580421351?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:01","pubTimestamp":1762174880,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. will host a conference call and webcast to discuss its third quarter 2025 financial results on November 10, 2025. Results will be released on the Events & Presentations page in the Investors & Media section of the Company's website. A replay of the webcast will be available for 30 days following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL2yQZYq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","SPRY","NDAQ","IE00B64PRP62.GBP","BK4588"],"gpt_icon":0},{"id":"2580218948","title":"ARS Pharmaceuticals Reports Real-World Success of Intranasal Epinephrine neffy in Treating Anaphylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2580218948","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580218948?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:45","pubTimestamp":1762173913,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. has announced that it will present new real-world data on its intranasal epinephrine spray, neffy, at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology , scheduled for November 6-10, 2025, in Orlando, FL. The presentations will include one late-breaking oral abstract and six poster presentations. According to the company, the oral presentation will report that approximately 9 out of 10 patients experiencing anaphylaxis were effectively treated with a single dose of neffy. Additionally, case reports will detail the use of neffy in patients undergoing oral food challenges or allergy immunotherapy, including instances where patients presented with nasal congestion or rhinorrhea as part of their anaphylactic reaction. These results will be presented at the upcoming ACAAI meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL7jtVS7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4112","IE00BGHQF748.EUR","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","LU2210150020.SGD","BK4139","SPRY","LU2095319765.USD","IE00B3QW5Z07.USD","BK4585","BK4588","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2573892378","title":"ARS Pharmaceuticals Says European Patent Office Upholds Nasal Spray Epinephrine Patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2573892378","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573892378?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:31","pubTimestamp":1759926713,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  said Wednesday that the European Patent Office has upheld all claims in one of its key patents related to its nasal epinephrine spray, covering formulations that include ingredients like Intravail.The company said the patent is valid in over 30 European countries and protects the product through at least 2039.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2573923208","title":"European Patent Office Upholds ARS Patent for Nasal Spray to Treat Allergic Reaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2573923208","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573923208?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:30","pubTimestamp":1759926600,"startTime":"0","endTime":"0","summary":"The European Patent Office upheld ARS Pharmaceuticals' novel claims in its patent for an epinephrine nasal spray to treat allergic reactions, the company said.ARS said its global intellectual property related to the nasal spray, called neffy, provides coverage until at least 2039.Earlier this year, the U.S. Patent and Trademark Office upheld a similar ARS patent following an independent challenge.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2573492804","title":"BRIEF-ARS Pharmaceuticals Receives Favorable Decision From European Patent Office On Patent Related To Neffy® (Epinephrine Nasal Spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2573492804","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573492804?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:10","pubTimestamp":1759925422,"startTime":"0","endTime":"0","summary":"BRIEF-ARS Pharmaceuticals Receives Favorable Decision From European Patent Office On Patent Related To Neffy (Epinephrine Nasal Spray)Oct 8 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:ARS PHARMACEUTICA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nFWN3VP1I1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2573928489","title":"ARS Pharmaceuticals : Global Intellectual Property Portfolio Related to Neffy Provides Coverage Until at Least 2039","url":"https://stock-news.laohu8.com/highlight/detail?id=2573928489","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573928489?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:00","pubTimestamp":1759924846,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nFWN3VP1I1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2571350848","title":"ARS Pharmaceuticals Secures Up to $250 Million Loan Facility from RA Capital and OMERS Life Sciences to Accelerate neffy® Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2571350848","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571350848?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:05","pubTimestamp":1759176320,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Secures Up to $250 Million Loan Facility from RA Capital and OMERS Life Sciences to Accelerate neffy Commercialization. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on September 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL24ZQ1k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","NDAQ","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2095319765.USD","SPRY","IE00BKPKM429.USD","BK4588","LU0314104364.USD"],"gpt_icon":0},{"id":"2571890350","title":"ARS Pharmaceuticals Secures up to $250 Million Loan Facility With Ra Capital Management and Omers Life Sciences to Accelerate U.S. Commercialization of Neffy®","url":"https://stock-news.laohu8.com/highlight/detail?id=2571890350","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571890350?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:05","pubTimestamp":1759176301,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUABCCW6S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2571508933","title":"ARS Pharmaceuticals Inc -  ARS Pharma Borrows Initial $100 Mln to Accelerate Neffy Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2571508933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571508933?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:05","pubTimestamp":1759176301,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUABCCW6S:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2568298235","title":"Sector Update: Health Care Stocks Mixed Friday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2568298235","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568298235?lang=en_us&edition=fundamental","pubTime":"2025-09-20 01:55","pubTimestamp":1758304533,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed Friday afternoon, with the NYSE Health Care Index easing 0.01% and the Health Care Select Sector SPDR Fund  adding 0.1%.The iShares Biotechnology ETF  was shedding 0.5%.In corporate news, Amgen's  Uplizna has received a positive opinion from the European Medicines Agency's human medicines committee recommending its approval for adults with active immunoglobulin G4-related disease, a rare autoimmune disorder with no authorized treatments in the EU. Amgen shares rose past 3%.InterCure  shares were down 1.4% after it said Friday it has agreed to buy medical cannabis brand and technology company Botanico, also known as ISHI, in a two-phase deal valued at about 10% of InterCure's outstanding shares on a fully-diluted basis.ARS Pharmaceuticals  shares added nearly 1% after the company said its nasal spray Neffy has received regulatory approval in Japan for the emergency treatment of allergic reactions, including anaphylaxis.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","XBI","IE00B2B36J28.USD","BK4599","LU2242646821.SGD","BK4139","LU0289739699.SGD","LU0889565916.HKD","SPRY","BK4534","BK4007","BK4533","LU1023059063.AUD","LU1983299246.USD","BK4585","LU0122379950.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","IE00BJJMRZ35.SGD","INCR","LU1057294990.SGD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU2089984988.USD","SG9999001440.SGD","IE00BJT1NW94.SGD","IE0009355771.USD","LU2112291526.USD","IE0002141913.USD","BK4581","BK4566","XLV","LU2242652126.USD","IBB","LU0868494617.USD","LU1061106388.HKD","AMGN","LU0058720904.USD","LU2468319806.SGD","LU1571399168.USD","LABU"],"gpt_icon":0},{"id":"2568657912","title":"Sector Update: Health Care Stocks Rise Pre-Bell Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2568657912","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568657912?lang=en_us&edition=fundamental","pubTime":"2025-09-19 21:16","pubTimestamp":1758287777,"startTime":"0","endTime":"0","summary":"Health care stocks were rising pre-bell Friday, with the Health Care Select Sector SPDR Fund (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) 0.2% higher.ARS Pharmaceuticals (SPRY) shares were up","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4581","XBI","BK4585","NUVB","BK4007","IBB","LABU","XLV","SPRY","BK4588","KALV"],"gpt_icon":0},{"id":"2568263288","title":"ARS Pharmaceuticals Says Japan Regulator Approves Neffy Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2568263288","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568263288?lang=en_us&edition=fundamental","pubTime":"2025-09-19 20:45","pubTimestamp":1758285950,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  said Friday that its nasal spray neffy has received regulatory approval in Japan for the emergency treatment of allergic reactions, including anaphylaxis.The approval by Japan's Pharmaceuticals and Medical Devices Agency covers 1 mg and 2 mg doses, the company said.Japanese pharmaceutical company Alfresa Holdings has the rights to commercialize neffy in Japan under a 2020 agreement, ARS said.ARS said it is eligible to receive a final regulatory milestone of $2 million after listing neffy on the Japanese National Health Insurance drug price list, and to sell the drug to Alfresa at a transfer price.Alfressa expects to launch the nasal spray in Q4, ARS said.Shares of ARS were up 5% in recent Friday premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2568268367","title":"ARS Pharmaceuticals Inc - Neffy Expected to Be Available in Japan in Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2568268367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568268367?lang=en_us&edition=fundamental","pubTime":"2025-09-19 20:00","pubTimestamp":1758283226,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250919:nTUA5H8YHC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2568020250","title":"Neffy® (Epinephrine Nasal Spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (Anaphylaxis)","url":"https://stock-news.laohu8.com/highlight/detail?id=2568020250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568020250?lang=en_us&edition=fundamental","pubTime":"2025-09-19 20:00","pubTimestamp":1758283226,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250919:nTUA5H8YHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":45,"code":"91000000","status":"200"}]}}